CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 400 enrolled
Drug / intervention
Inclisirandrug
Likely dose
Inclisiran 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04873934
NCT04873934Phase 3Completed
CompareCT.gov

A Randomized, Controlled, Multicenter, Open-label Trial Comparing a Hospital Post-discharge Care Pathway Involving Aggressive LDL-C Management That Includes Inclisiran With Usual Care Versus Usual Care Alone in Patients With a Recent Acute Coronary Syndrome (VICTORION-INCEPTION)

Novartis Pharmaceuticals·interventional·Posted May 5, 2021·Updated Oct 16, 2025

In Brief

A Phase 3 clinical trial evaluating Inclisiran for Acute Coronary Syndrome. Completed, enrolled 400 participants across 88 sites.

Detailed Summary

The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) despite being treated with a statin drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMay 5, 2021
Enrollment StartJun 24, 2021
Primary CompletionAug 7, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.2 years ago

Interventions

Inclisirandrug

Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)